Based on last week's filing, the drug should move into clinical testing by late July. As a reminder, Kalbitor treats attacks, but 2930 would be taken to prevent attacks. Presumably, this would lead to much higher volume sales and a greater degree of loyalty among patients.
I like the stock price action lately. Slow and steady rises on generally good volume.
I agree----and this adds to their 'irons in the fire.'
For those who like to fantasize (but who don't ACT on those fantasies), please recall that right after its initial offering, DYAX sold for $40/share.